During the last years, the median overall survival (OS) among patients with advanced non‐small cell lung cancer (NSCLC) has increased, partly due to the development and emerging use of immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD‐1) and PD‐ligand 1 (PD‐L1) [2, 3]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.